VM BioPharma begins dosing in Phase III trial of VM202 for NHU and PAD
Korean biopharmaceutical company ViroMed ’s US division VM BioPharma has begun dosing patients with VM202 in a Phase III clinical trial to treat non-healing diabetic foot ulcers (NHU) and associated peripheral artery disease (PAD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Diabetes | Diabetic Ulcers | Endocrinology | Peripheral Vascular Disease (PVD) | Pharmaceuticals